Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

NCT03155932 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT03155932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03155932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
December 29, 2017
Completion date
January 31, 2019
Enrollment
2 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis